BlackRock Advisors’s CytomX Therapeutics CTMX Stock Holding History

BlackRock Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$138K	Sell	12,583 -320,760	-96%	-$3.89M	﹤0.01%	2889
2016 Q3	$5.23M	Sell	333,343 -209,041	-39%	-$2.53M	0.01%	1113
2016 Q2	$5.54M	Buy	542,384 +539,834	+21,170%	+$6.16M	0.01%	1061
2016 Q1	$33K	Hold	2,550	–	–	﹤0.01%	3290
2015 Q4	$53K	Buy	+2,550	New	+$40.3K	﹤0.01%	3165

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock Advisors's CTMX Position: Q4 2016 in Review

BlackRock Advisors reduced its CytomX Therapeutics (CTMX) stake by 96% in Q4 2016, selling an estimated $3.89M and leaving 12,583 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #2889.

BlackRock Advisors first reported a position in CTMX in Q4 2015 and has held it in 5 quarters since. The position peaked at $5.54M in Q2 2016. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

BlackRock Advisors held 12,583 shares of CytomX Therapeutics worth $138K as of Q4 2016.
BlackRock Advisors sold 320,760 CytomX Therapeutics shares in Q4 2016, an estimated $3.89M.
CytomX Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2889 holding.
BlackRock Advisors first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 5 quarters since.
BlackRock Advisors's CytomX Therapeutics position peaked at $5.54M in Q2 2016.
68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.